Cargando…

First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report

Background. Patients with metastatic or radioactive iodine refractory papillary thyroid carcinoma (PTC) have poor prognosis due to ineffective therapy for this condition beyond surgery and radioactive iodine (RAI or (131)I). BRAF mutation occurs in more than 44% of PCT. Tyrosine kinase inhibitors, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dao, Bao D., Lingvay, Ildiko, Sailors, Joseph, Landay, Michael, Shapiro, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748501/ https://www.ncbi.nlm.nih.gov/pubmed/26904701 http://dx.doi.org/10.1177/2324709615603723

Ejemplares similares

Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer
por: Han, Sang-Ah, et al.
Publicado: (2014)

Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report
por: Amoako-Tuffour, Yaw, et al.
Publicado: (2017)

MON-494 Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to the Treatment: Total Thyroidectomy Versus Total Thyroidectomy with Radioactive Iodine Remnant Ablation
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Radioactive Iodine Remnant Ablation: The Beta-knife Completion Thyroidectomy
por: Gulec, Seza, et al.
Publicado: (2017)

The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer
por: Wang, Xiaofei, et al.
Publicado: (2020)

“Adjuvant Radioactive iodine 133 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience”
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2015)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
por: Creach, Kimberly M., et al.
Publicado: (2012)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Radioactive Iodine Ablation Decrease Recurrences in Papillary Thyroid Microcarcinoma with Lateral Lymph Node Metastasis in Chinese Patients
por: Xue, Shuai, et al.
Publicado: (2017)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Experiences of Korean patients with thyroid cancer receiving radioactive iodine therapy after total thyroidectomy
por: Shin, Jeong Ha, et al.
Publicado: (2021)

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial
por: Jammah, Anwar A., et al.
Publicado: (2021)

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis
por: Zhao, Min, et al.
Publicado: (2022)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER
por: Tang, Jianing, et al.
Publicado: (2018)

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer
por: Liu, Lina, et al.
Publicado: (2022)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

Rate of thyroglossal duct remnant visualization after total thyroidectomy for differentiated thyroid carcinoma and its impact on clinical outcome of radioactive iodine (I-131) ablation
por: Mohamed Sayed, Mohamed Hosny, et al.
Publicado: (2015)

How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation?
por: Sawka, A M, et al.
Publicado: (2011)

Trends in radioactive iodine treatment after total thyroidectomy in Italy, 2001–2018
por: Dal Maso, Luigino, et al.
Publicado: (2023)

Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy
por: Yun, Canhua, et al.
Publicado: (2021)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
por: Chen, Shitu, et al.
Publicado: (2020)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine
por: Adamska, Agnieszka, et al.
Publicado: (2021)

Responses to the First Radioactive Iodine Treatment After Targeted Therapy for Aggressive Papillary Thyroid Cancers
por: Soe, Myat Han, et al.
Publicado: (2021)

Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
por: Li, Wanting, et al.
Publicado: (2023)

Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma
por: Kim, Eun Young, et al.
Publicado: (2017)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAF(V600E) mutation treated with dabrafenib–trametinib: a case report
por: Martín-Soberón, M. C., et al.
Publicado: (2021)

Clinical Treatment Efficacy of Total Thyroidectomy Combined with Radioactive Iodine on Treatment of Thyroid Cancer and Its Effect on the Quality of Life of Patients
por: YANG, Yong, et al.
Publicado: (2019)

Radioactive Iodine Following Total Thyroidectomy Is Comparable to Lobectomy in Low/Intermediate-Risk Differentiated Thyroid Carcinoma: A Meta-Analysis
por: Altedlawi Albalawi, Ibrahim A, et al.
Publicado: (2020)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9vk5s5bg516j4gsa7524p35c31